MDGN 4.81 Medgenics Inc. Common Stock $MDGN Hit a
Post# of 32
Posted On: 11/06/2014 11:01:28 PM
MDGN 4.81 Medgenics Inc. Common Stock $MDGN Hit a 52 week low of 4.25 Closing the day 11/06/14 at 4.81 +0.15 +3.22% With a day low of 4.25 and a total volume of 51,602.
MDGN Recent Posts: http://investorshangout.com/Medgenics-Inc-Com...DGN-56983/
MDGN Medgenics Inc. Common Stock Recent Headline News
Medgenics to Host Conference Call to Announce Third Quarter 2014 Results and Provide Initial Clinical Data on MDGN-201 on October 15, 2014
GlobeNewswire - Wed Oct 08, 7:35AM CDT
Medgenics, Inc. (NYSE:MDGN) will host a conference call and live audio webcast on Wednesday, October 15, 2014 at 9 a.m. EDT to discuss third quarter 2014 financial and operational results and to provide initial clinical data from the ongoing MDGN-201 clinical trial, "Safety and Efficacy of Sustained Erythropoietin Therapy of Anemia in Chronic Kidney Disease Patients and End-Stage Renal Disease (ESRD) Dialysis Patients using TARGTEPO (formerly known as EPODURE BioPump).
MDGN: 4.81 (+0.15)
Medgenics to Present Initial Clinical Data From MDGN-201 Study at European Society of Gene and Cell Therapy Congress
GlobeNewswire - Tue Oct 07, 7:39AM CDT
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that initial data from its ongoing Phase 1/2 clinical trial of MDGN-201 (TARGTEPO), formerly known as EPODURE, will be presented at the 22 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) being held in The Hague, Netherlands from October 23-26, 2014.
MDGN: 4.81 (+0.15)
Medgenics to Announce Third Quarter 2014 Results and Provide Initial Clinical Data on MDGN-201 (EPODURE(TM)) Trial on October 15, 2014
GlobeNewswire - Wed Sep 24, 7:30AM CDT
Medgenics, Inc. (NYSE:MDGN) will host a conference call and live audio webcast on Wednesday, October 15, 2014 at 9 a.m. EDT to discuss third quarter 2014 financial and operational results and to provide initial clinical data from the ongoing MDGN-201 trial, "Safety and Efficacy of Sustained Erythropoietin Therapy of Anemia in Chronic Kidney Disease Patients and End-Stage Renal Disease (ESRD) Dialysis Patients Using EPODURE BioPump."
MDGN: 4.81 (+0.15)
Medgenics Announces the Appointment of Scott Applebaum as Chief Legal Officer
GlobeNewswire - Wed Sep 10, 7:30AM CDT
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced the appointment of Scott Applebaum as Chief Legal Officer.
MDGN: 4.81 (+0.15)
Renal Anemia - Pipeline Review, H2 2014 - 22 Companies & 25 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xpp5q/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Medgenics Inc. - Amgen Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - FibroGen, Inc. - Japan Tobacco Inc. - Zydus Cadila Healthcare Limited - Bayer AG - 3SBio Inc. - ProMetic Life Sciences Inc. - JCR Pharmaceuticals Co., Ltd. - CCM Duopharma Biotech Bhd. - Panacea Biotec Limited - Affymax, Inc. - Myungmoon pharmaceutical Co.,Ltd. - Intas Pharmaceuticals Ltd. - Acceleron Pharma, Inc. - Pieris AG - Noxxon Pharma AG - Aprogen, Inc. - Dong-A Socio Group Drug Profiles - peginesatide - darbepoetin alfa - epoetin - epoetin alfa - Peg-EPO - roxadustat - sotatercept - GSK-1278863 - lexaptepid pegol - molidustat - MDGN-201 - PEG-EPO - FG-2216 - PRS-080 - epoetin alfa - JTZ-951 - epoetin alfa - DS-1093 - NuPIAO - PBI-1402 - PBI-4050 - ZP-EPO - darbepoetin alfa - MM-P01-01 - Recombinant Protein for Renal Anemia For more information visit http://www.researchandmarkets.com/research/3x...nal_anemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MDGN: 4.81 (+0.15), AMGN: 160.35 (+1.41), GSK: 44.75 (-0.39), XLRN: 34.14 (+0.92)
Medgenics Reports Second Quarter Financial Results
GlobeNewswire - Wed Jul 16, 7:43AM CDT
Medgenics, Inc. (NYSE MKT:MDGN) (the Company), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today reported financial results for the three and six months ended June 30, 2014 and the filing with the U.S. Securities and Exchange Commission (SEC) of the Company's Quarterly Report on Form 10-Q. The Form 10-Q includes unaudited interim consolidated financial statements containing the information presented below, as well as additional information regarding the Company. The Form 10-Q is available at www.sec.gov and at www.medgenics.com.
MDGN: 4.81 (+0.15)
Medgenics Announces Global Head, Research and Development, Garry Neil, M.D. Receives FDA Commissioner's Special Citation Award
GlobeNewswire - Wed Jun 18, 7:30PM CDT
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Garry Neil, M.D., Global Head, Research and Development, has been awarded the Food and Drug Administration's (FDA) Commissioner's Special Citation. The Citation was established as an expression of the Commissioner's personal appreciation, recognizing outstanding and significant service in the public interest related to activities of the FDA. Dr. Neil has been extensively involved with many aspects of FDA policy work, including his work with the Reagan-Udall Foundation for the FDA. The Foundation fosters collaborations between patient groups, industry, academia, and FDA scientists to design and conduct regulatory science research.
MDGN: 4.81 (+0.15)
Medgenics to Present at Two Upcoming Healthcare Investor Conferences
GlobeNewswire - Mon Jun 16, 9:38AM CDT
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that members of the senior management team will be participating in the following upcoming healthcare investor conferences.
MDGN: 4.81 (+0.15)
Faruqi & Faruqi, LLP Launches An Investigation Against Medgenics, Inc. (MDGN) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
PR Newswire - Fri Mar 14, 6:15PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Medgenics, Inc. ("Medgenics" or the "Company"
(NYSE: MDGN) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders' approval for an amendment to the Medgenics, Inc. Stock Incentive Plan.
MDGN: 4.81 (+0.15)
Medgenics, Inc. to Present at the 26th Annual ROTH Capital Growth Conference
GlobeNewswire - Wed Mar 05, 7:30AM CST
Medgenics, Inc. (NYSE:MDGN) (AIM:MEDU) (AIM:MEDG), the developer of BioPump(TM), a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Michael Cola, President and CEO, will present a corporate overview at the 26 Annual ROTH Capital Growth Conference in Laguna Niguel on Tuesday, March 11, 2014 at 8:00am PDT.
MDGN: 4.81 (+0.15)
SOL J. BARER of Medgenics, Inc. (MDGN)-NYSE M bought Shares of MDGN
M2 - Fri Sep 20, 10:10AM CDT
Reported by InsiderCow.com at 2013-09-19 15:23:19 ET
MDGN: 4.81 (+0.15)
Medgenics Announces New Executive Leadership Team
Business Wire - Mon Sep 16, 6:30AM CDT
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces the appointment of a new executive leadership team with the goal of accelerating the development of the company's gene therapy platform and maximizing the value of the company's technology assets. The new executives are Michael Cola, President and Chief Executive Officer, John Leaman, M.D., Chief Financial Officer, and Garry Neil, M.D., Global Head of Research and Development. In addition, on September 13, 2013, Mr. Cola joined the Medgenics' Board of Directors.
JNJ: 109.01 (+0.19), SFE: 20.04 (+0.09), MDGN: 4.81 (+0.15)
Anemia - Pipeline Review, H2 2013
M2 - Fri Sep 06, 2:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sblm26/anemia_pipeline) has announced the addition of the "Anemia - Pipeline Review, H2 2013" report to their offering. 'Anemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anemia. Scope - A snapshot of the global therapeutic scenario for Anemia. - A review of the Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Anemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Anemia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Anemia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Johnson & Johnson Hospira, Inc. Medgenics Inc. AMAG Pharmaceuticals, Inc. Medinox, Inc. Amgen Inc. Eli Lilly and Company GlaxoSmithKline plc Sangart, Inc. Rockwell Medical Technologies, Inc. Daiichi Sankyo Company, Ltd Lentigen Corporation Sangamo BioSciences, Inc. Gamida Cell Ltd. FibroGen, Inc. Reliance Life Sciences Pvt. Ltd. Novartis AG and many more... For more information visit http://www.researchandmarkets.com/research/sb...a_pipeline About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
JNJ: 109.01 (+0.19), MDGN: 4.81 (+0.15), SGMO: 11.64 (+0.51), AMGN: 160.35 (+1.41), LLY: 66.96 (-0.03), AMAG: 34.12 (+0.34), RMTI: 9.33 (+0.15), GSK: 44.75 (-0.39), NVS: 92.03 (-0.60)
Hepatitis C - Pipeline Review, H2 2013
M2 - Mon Sep 02, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wq4dm8/hepatitis_c) has announced the addition of the "Hepatitis C - Pipeline Review, H2 2013" report to their offering. 'Hepatitis C - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis C, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis C. Scope - A snapshot of the global therapeutic scenario for Hepatitis C. - A review of the Hepatitis C products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hepatitis C pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH F. Hoffmann-La Roche Ltd. United Therapeutics Corporation Medgenics Inc. Valeant Pharmaceuticals International GlaxoSmithKline plc Tekmira Pharmaceuticals Corp. Inovio Biomedical Corporation Idenix Pharmaceuticals, Inc. Gilead Sciences, Inc. Biotest AG Merck & Co., Inc. Lentigen Corporation BioLineRx, Ltd. Biotron Limited Novartis AG Isotechnika Pharma Inc. Achillion Pharmaceuticals, Inc. Chugai Pharmaceutical Co. Ltd and many more.... For more information visit http://www.researchandmarkets.com/research/wq...epatitis_c About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MDGN: 4.81 (+0.15), UTHR: 125.33 (+2.12), TKMR: 15.76 (+0.64), BMY: 58.46 (+0.64), GSK: 44.75 (-0.39), VRX.TO: 147.18 (-2.87), INO: 11.07 (-0.16), JNJ: 109.01 (+0.19), GILD: 106.94 (+0.89), ACHN: 10.26 (+0.11), MRK: 59.26 (-0.31), IDIX: 24.50 (+0.05), NVS: 92.03 (-0.60)
Medgenics Awarded $1.9 Million Grant from the Israeli Office of the Chief Scientist
Business Wire - Tue Jul 09, 8:00AM CDT
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the "Company" , the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported that its wholly owned subsidiary, Medgenics Medical Israel Ltd. (MMI), was awarded a government grant of up to NIS 6.7 million (approximately USD 1.9 million), from the Office of the Chief Scientist (OCS) at the Ministry of Industry, Trade and Labor of Israel.
MDGN: 4.81 (+0.15)
Medgenics to Present at the 8th Annual JMP Securities Healthcare Conference
Business Wire - Mon Jul 08, 9:24AM CDT
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the "Company" , the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of Medgenics, will be presenting a corporate overview at the 8th Annual JMP Securities Healthcare Conference on Wednesday, July 10th at 12:00 noon Eastern time at The St. Regis New York.
MDGN: 4.81 (+0.15)
Medgenics Reports First Quarter 2013 Financial Results
Business Wire - Thu May 09, 8:15AM CDT
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the "Company" , the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported financial results for the three months ended March 31, 2013 and the filing with the U.S. Securities and Exchange Commission ("SEC" of the Company's Quarterly Report on Form 10-Q. The Form 10-Q includes unaudited interim consolidated financial statements containing the information presented below, as well as additional information regarding the Company. The Form 10-Q is available at www.sec.gov and at www.medgenics.com.
MDGN: 4.81 (+0.15)
Medgenics Announces Results of 2013 Annual Meeting of Stockholders
Business Wire - Wed May 01, 8:15AM CDT
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the "Company" or "Medgenics" ,, the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announces that all resolutions proposed at the Company's Annual Meeting of Stockholders held yesterday were duly passed.
MDGN: 4.81 (+0.15)
Medgenics Reports Positive Interim Results from Ongoing Phase IIa Study of EPODURE to Treat Anemia in Dialysis Patients
Business Wire - Thu Apr 25, 8:15AM CDT
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the "Company" , the developer of Biopump(TM), a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today provided an update on results from the first four patients treated thus far in its ongoing Phase IIa clinical trial in Israel of EPODURE(TM) Biopumps to treat anemia in patients on dialysis with end-stage renal disease ("ESRD" .
MDGN: 4.81 (+0.15)
MDGN Recent Posts: http://investorshangout.com/Medgenics-Inc-Com...DGN-56983/
MDGN Medgenics Inc. Common Stock Recent Headline News
Medgenics to Host Conference Call to Announce Third Quarter 2014 Results and Provide Initial Clinical Data on MDGN-201 on October 15, 2014
GlobeNewswire - Wed Oct 08, 7:35AM CDT
Medgenics, Inc. (NYSE:MDGN) will host a conference call and live audio webcast on Wednesday, October 15, 2014 at 9 a.m. EDT to discuss third quarter 2014 financial and operational results and to provide initial clinical data from the ongoing MDGN-201 clinical trial, "Safety and Efficacy of Sustained Erythropoietin Therapy of Anemia in Chronic Kidney Disease Patients and End-Stage Renal Disease (ESRD) Dialysis Patients using TARGTEPO (formerly known as EPODURE BioPump).
MDGN: 4.81 (+0.15)
Medgenics to Present Initial Clinical Data From MDGN-201 Study at European Society of Gene and Cell Therapy Congress
GlobeNewswire - Tue Oct 07, 7:39AM CDT
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that initial data from its ongoing Phase 1/2 clinical trial of MDGN-201 (TARGTEPO), formerly known as EPODURE, will be presented at the 22 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) being held in The Hague, Netherlands from October 23-26, 2014.
MDGN: 4.81 (+0.15)
Medgenics to Announce Third Quarter 2014 Results and Provide Initial Clinical Data on MDGN-201 (EPODURE(TM)) Trial on October 15, 2014
GlobeNewswire - Wed Sep 24, 7:30AM CDT
Medgenics, Inc. (NYSE:MDGN) will host a conference call and live audio webcast on Wednesday, October 15, 2014 at 9 a.m. EDT to discuss third quarter 2014 financial and operational results and to provide initial clinical data from the ongoing MDGN-201 trial, "Safety and Efficacy of Sustained Erythropoietin Therapy of Anemia in Chronic Kidney Disease Patients and End-Stage Renal Disease (ESRD) Dialysis Patients Using EPODURE BioPump."
MDGN: 4.81 (+0.15)
Medgenics Announces the Appointment of Scott Applebaum as Chief Legal Officer
GlobeNewswire - Wed Sep 10, 7:30AM CDT
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced the appointment of Scott Applebaum as Chief Legal Officer.
MDGN: 4.81 (+0.15)
Renal Anemia - Pipeline Review, H2 2014 - 22 Companies & 25 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xpp5q/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Medgenics Inc. - Amgen Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - FibroGen, Inc. - Japan Tobacco Inc. - Zydus Cadila Healthcare Limited - Bayer AG - 3SBio Inc. - ProMetic Life Sciences Inc. - JCR Pharmaceuticals Co., Ltd. - CCM Duopharma Biotech Bhd. - Panacea Biotec Limited - Affymax, Inc. - Myungmoon pharmaceutical Co.,Ltd. - Intas Pharmaceuticals Ltd. - Acceleron Pharma, Inc. - Pieris AG - Noxxon Pharma AG - Aprogen, Inc. - Dong-A Socio Group Drug Profiles - peginesatide - darbepoetin alfa - epoetin - epoetin alfa - Peg-EPO - roxadustat - sotatercept - GSK-1278863 - lexaptepid pegol - molidustat - MDGN-201 - PEG-EPO - FG-2216 - PRS-080 - epoetin alfa - JTZ-951 - epoetin alfa - DS-1093 - NuPIAO - PBI-1402 - PBI-4050 - ZP-EPO - darbepoetin alfa - MM-P01-01 - Recombinant Protein for Renal Anemia For more information visit http://www.researchandmarkets.com/research/3x...nal_anemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MDGN: 4.81 (+0.15), AMGN: 160.35 (+1.41), GSK: 44.75 (-0.39), XLRN: 34.14 (+0.92)
Medgenics Reports Second Quarter Financial Results
GlobeNewswire - Wed Jul 16, 7:43AM CDT
Medgenics, Inc. (NYSE MKT:MDGN) (the Company), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today reported financial results for the three and six months ended June 30, 2014 and the filing with the U.S. Securities and Exchange Commission (SEC) of the Company's Quarterly Report on Form 10-Q. The Form 10-Q includes unaudited interim consolidated financial statements containing the information presented below, as well as additional information regarding the Company. The Form 10-Q is available at www.sec.gov and at www.medgenics.com.
MDGN: 4.81 (+0.15)
Medgenics Announces Global Head, Research and Development, Garry Neil, M.D. Receives FDA Commissioner's Special Citation Award
GlobeNewswire - Wed Jun 18, 7:30PM CDT
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Garry Neil, M.D., Global Head, Research and Development, has been awarded the Food and Drug Administration's (FDA) Commissioner's Special Citation. The Citation was established as an expression of the Commissioner's personal appreciation, recognizing outstanding and significant service in the public interest related to activities of the FDA. Dr. Neil has been extensively involved with many aspects of FDA policy work, including his work with the Reagan-Udall Foundation for the FDA. The Foundation fosters collaborations between patient groups, industry, academia, and FDA scientists to design and conduct regulatory science research.
MDGN: 4.81 (+0.15)
Medgenics to Present at Two Upcoming Healthcare Investor Conferences
GlobeNewswire - Mon Jun 16, 9:38AM CDT
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that members of the senior management team will be participating in the following upcoming healthcare investor conferences.
MDGN: 4.81 (+0.15)
Faruqi & Faruqi, LLP Launches An Investigation Against Medgenics, Inc. (MDGN) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
PR Newswire - Fri Mar 14, 6:15PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Medgenics, Inc. ("Medgenics" or the "Company"
(NYSE: MDGN) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders' approval for an amendment to the Medgenics, Inc. Stock Incentive Plan. MDGN: 4.81 (+0.15)
Medgenics, Inc. to Present at the 26th Annual ROTH Capital Growth Conference
GlobeNewswire - Wed Mar 05, 7:30AM CST
Medgenics, Inc. (NYSE:MDGN) (AIM:MEDU) (AIM:MEDG), the developer of BioPump(TM), a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Michael Cola, President and CEO, will present a corporate overview at the 26 Annual ROTH Capital Growth Conference in Laguna Niguel on Tuesday, March 11, 2014 at 8:00am PDT.
MDGN: 4.81 (+0.15)
SOL J. BARER of Medgenics, Inc. (MDGN)-NYSE M bought Shares of MDGN
M2 - Fri Sep 20, 10:10AM CDT
Reported by InsiderCow.com at 2013-09-19 15:23:19 ET
MDGN: 4.81 (+0.15)
Medgenics Announces New Executive Leadership Team
Business Wire - Mon Sep 16, 6:30AM CDT
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces the appointment of a new executive leadership team with the goal of accelerating the development of the company's gene therapy platform and maximizing the value of the company's technology assets. The new executives are Michael Cola, President and Chief Executive Officer, John Leaman, M.D., Chief Financial Officer, and Garry Neil, M.D., Global Head of Research and Development. In addition, on September 13, 2013, Mr. Cola joined the Medgenics' Board of Directors.
JNJ: 109.01 (+0.19), SFE: 20.04 (+0.09), MDGN: 4.81 (+0.15)
Anemia - Pipeline Review, H2 2013
M2 - Fri Sep 06, 2:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sblm26/anemia_pipeline) has announced the addition of the "Anemia - Pipeline Review, H2 2013" report to their offering. 'Anemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anemia. Scope - A snapshot of the global therapeutic scenario for Anemia. - A review of the Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Anemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Anemia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Anemia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Johnson & Johnson Hospira, Inc. Medgenics Inc. AMAG Pharmaceuticals, Inc. Medinox, Inc. Amgen Inc. Eli Lilly and Company GlaxoSmithKline plc Sangart, Inc. Rockwell Medical Technologies, Inc. Daiichi Sankyo Company, Ltd Lentigen Corporation Sangamo BioSciences, Inc. Gamida Cell Ltd. FibroGen, Inc. Reliance Life Sciences Pvt. Ltd. Novartis AG and many more... For more information visit http://www.researchandmarkets.com/research/sb...a_pipeline About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
JNJ: 109.01 (+0.19), MDGN: 4.81 (+0.15), SGMO: 11.64 (+0.51), AMGN: 160.35 (+1.41), LLY: 66.96 (-0.03), AMAG: 34.12 (+0.34), RMTI: 9.33 (+0.15), GSK: 44.75 (-0.39), NVS: 92.03 (-0.60)
Hepatitis C - Pipeline Review, H2 2013
M2 - Mon Sep 02, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wq4dm8/hepatitis_c) has announced the addition of the "Hepatitis C - Pipeline Review, H2 2013" report to their offering. 'Hepatitis C - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis C, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis C. Scope - A snapshot of the global therapeutic scenario for Hepatitis C. - A review of the Hepatitis C products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hepatitis C pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH F. Hoffmann-La Roche Ltd. United Therapeutics Corporation Medgenics Inc. Valeant Pharmaceuticals International GlaxoSmithKline plc Tekmira Pharmaceuticals Corp. Inovio Biomedical Corporation Idenix Pharmaceuticals, Inc. Gilead Sciences, Inc. Biotest AG Merck & Co., Inc. Lentigen Corporation BioLineRx, Ltd. Biotron Limited Novartis AG Isotechnika Pharma Inc. Achillion Pharmaceuticals, Inc. Chugai Pharmaceutical Co. Ltd and many more.... For more information visit http://www.researchandmarkets.com/research/wq...epatitis_c About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MDGN: 4.81 (+0.15), UTHR: 125.33 (+2.12), TKMR: 15.76 (+0.64), BMY: 58.46 (+0.64), GSK: 44.75 (-0.39), VRX.TO: 147.18 (-2.87), INO: 11.07 (-0.16), JNJ: 109.01 (+0.19), GILD: 106.94 (+0.89), ACHN: 10.26 (+0.11), MRK: 59.26 (-0.31), IDIX: 24.50 (+0.05), NVS: 92.03 (-0.60)
Medgenics Awarded $1.9 Million Grant from the Israeli Office of the Chief Scientist
Business Wire - Tue Jul 09, 8:00AM CDT
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the "Company"
, the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported that its wholly owned subsidiary, Medgenics Medical Israel Ltd. (MMI), was awarded a government grant of up to NIS 6.7 million (approximately USD 1.9 million), from the Office of the Chief Scientist (OCS) at the Ministry of Industry, Trade and Labor of Israel. MDGN: 4.81 (+0.15)
Medgenics to Present at the 8th Annual JMP Securities Healthcare Conference
Business Wire - Mon Jul 08, 9:24AM CDT
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the "Company"
, the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of Medgenics, will be presenting a corporate overview at the 8th Annual JMP Securities Healthcare Conference on Wednesday, July 10th at 12:00 noon Eastern time at The St. Regis New York. MDGN: 4.81 (+0.15)
Medgenics Reports First Quarter 2013 Financial Results
Business Wire - Thu May 09, 8:15AM CDT
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the "Company"
, the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported financial results for the three months ended March 31, 2013 and the filing with the U.S. Securities and Exchange Commission ("SEC" of the Company's Quarterly Report on Form 10-Q. The Form 10-Q includes unaudited interim consolidated financial statements containing the information presented below, as well as additional information regarding the Company. The Form 10-Q is available at www.sec.gov and at www.medgenics.com. MDGN: 4.81 (+0.15)
Medgenics Announces Results of 2013 Annual Meeting of Stockholders
Business Wire - Wed May 01, 8:15AM CDT
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the "Company" or "Medgenics"
,, the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announces that all resolutions proposed at the Company's Annual Meeting of Stockholders held yesterday were duly passed. MDGN: 4.81 (+0.15)
Medgenics Reports Positive Interim Results from Ongoing Phase IIa Study of EPODURE to Treat Anemia in Dialysis Patients
Business Wire - Thu Apr 25, 8:15AM CDT
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the "Company"
, the developer of Biopump(TM), a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today provided an update on results from the first four patients treated thus far in its ongoing Phase IIa clinical trial in Israel of EPODURE(TM) Biopumps to treat anemia in patients on dialysis with end-stage renal disease ("ESRD" . MDGN: 4.81 (+0.15)
(0)
(0)Aevi Genomic Medicine, Inc. (GNMX) Stock Research Links
Scroll down for more posts ▼